LENZ Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.51) Per Share, Leerink Partnrs Forecasts (NASDAQ:LENZ)

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for LENZ Therapeutics in a report released on Monday, April 15th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.51) per share for the quarter. Leerink Partnrs currently has a “Outperform” rating on the stock. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

A number of other research analysts also recently weighed in on the company. SVB Leerink started coverage on LENZ Therapeutics in a research note on Monday. They issued an “outperform” rating and a $32.00 price target for the company. Piper Sandler started coverage on LENZ Therapeutics in a research note on Wednesday, March 27th. They issued an “overweight” rating and a $28.00 price target for the company. Citigroup started coverage on LENZ Therapeutics in a research note on Wednesday, April 10th. They issued a “buy” rating and a $34.00 price target for the company. Finally, William Blair began coverage on LENZ Therapeutics in a research note on Monday. They issued an “outperform” rating for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $31.33.

LENZ Therapeutics Stock Performance

NASDAQ LENZ traded down $2.22 during trading hours on Wednesday, hitting $17.70. 84,141 shares of the company traded hands, compared to its average volume of 58,317. The stock has a market capitalization of $147.26 million, a PE ratio of -1.13 and a beta of 0.20. LENZ Therapeutics has a twelve month low of $14.07 and a twelve month high of $29.82.

Insider Activity

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. acquired 998,009 shares of the business’s stock in a transaction dated Thursday, March 21st. The stock was bought at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the transaction, the director now directly owns 3,319,339 shares in the company, valued at approximately $49,889,665.17. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 38.40% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.